Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Int Urogynecol J. 2014 Feb 11;25(9):1179–1184. doi: 10.1007/s00192-013-2325-2

Table 1.

Demographics of randomized and treated subjects

Characteristic Included in microbiome analyses
* p value All ABC (n=247a)
Yes (n=155) No (n=92)
Age at randomization (years) Mean (SD) 57.7 (11.3) 58.4 (11.2) 0.63 57.9 (11.3)
Hispanic or Latina: n (%) 33 (21) 11 (12) 0.06 44 (18)
Race: n (%) White 113 (73) 81 (88) 0.01 194 (79)
Black/African American 30 (19) 11 (12) 41 (17)
Other 12 (8) 0 12 (5
BMI Mean (SD) 32.9 (7.7) 31.8 (7.5) 0.29 32.5 (7.6)
Maritalstatus: n (%) Married/living as married 69 (45) 46 (50) 0.79 115 (47)
Divorced/separated/widowed 59 (38) 33 (36) 92 (37)
Other 1 (1) 0 1 (0
Single, never married 20 (13) 11 (12) 31 (13)
Some college or greater: n (%) 112 (72) 64 (70) 0.44 176 (71)
Health insurance: n (%) Private only 75 (48) 46 (50) 0.49 121 (49)
Medicare or Medicaid only 13 (8) 13 (14) 26 (11)
Other only 40 (26) 22 (24) 62 (25)
Combination of types 26 (17) 11 (12) 37 (15)
Not reported 1 (1) 0 1 (0 )
Smoking: n (%) Never 84 (54) 56 (61) 0.03 140 (57)
Previous 58 (37) 21 (23) 79 (32)
Current 13 (8) 14 (15) 27 (11)
Menopause: n (%) Pre-menopausal 23 (15) 14 (15) 0.85 37 (15)
Post-menopausal 123 (79) 71 (77) 194 (79)
Not sure 9 (6) 7 (8) 16 (6)
No prior anticholinergic exposure: n (%) 68 (44) 34 (37) 0.29 102 (41)
3-day diary total IE/day Mean (SD) 6.1 (3.3) 5.7 (3.0) 0.38 6.0 (3.2)
3-day diary urge IE/day Mean (SD) 5.1 (2.8) 4.8 (2.5) 0.44 5.0 (2.7)
Baseline PVR (mL) Mean (SD) 34.3 (46.7) 38.8 (44.8) 0.47 36.0 (46.0)

IE incontinent episodes, PVR postvoid residual urine, ABC Anticholinergic Versus Botulinum Toxin A Comparison Trial

*

p value based on the linear regression model with the treatment group as the explanatory value for continuous variables and Chi-squared tests for categorical measures

a

Of the 249 randomized individuals, 2 withdrew prior to treatment and did not provide baseline data